
Sign up to save your podcasts
Or


From AHA 2018, an analysis gives clue to how empagliflozin cuts cardiovascular risk, and study findings challenge cholesterol guidelines for patients with type 1 diabetes. Also, we take a closer look at how smoke-free policies affect blood pressure, and how magazine-ranked "Best Hospitals" actually perform.
The MDedge Cardiology team is back this week for part II of their conversation on the 2018 annual scientific session of the American Heart Association.
In this episode of the Cardiocast, the MDedge Cardiology team of reporters breaks down the 2018 annual scientific session of the American Heart Association.
This week on Cardiocast, guidelines for bradycardia set a new bar for shared decision-making in pacemaker placement, young adults with hypertension may be at higher CVD risk, how sleep quality affects cardiovascular risk, and a strong showing for exercise in patients with both heart failure and sleep apnea. Tune in next Friday for the most exciting news from the scientific sessions of the American Heart Association, as told by the reporters who cover it.
Today, an analysis that may challenge ASCVD guidelines, a new formula may predict adverse events from NSAIDs, a potentially important myocardial infarction risk factor is identified, and a diabetes drug gets a new cardiovascular indication.
Why wire-dependent fractional flow reserve may soon be obsolete; stroke risk after a myocardial infarction goes on three times longer than previously thought; poststroke dual-antiplatelet therapy should be cut short; and emergency departments are seeing results from greater use of high-sensitivity troponin T in chest pain patients.
This week, a revelation that coronary artery bypass grafting instead of percutaneous is safer as time goes by, a new index stretches the prognostic power of cardiac CT, a weight-loss drug cuts new-onset diabetes, and a controversial diet score is validated.
Angiography shouldn't end with a diagnosis of nonobstructive CAD, NSAIDs show cardiovascular and renal safety in the short term, a registry analysis supports use of direct oral anticoagulants over warfarin, and IVUS-guided stent placement bests angiography-led placement.
This week, the dangers of yo-yoing metabolic factors, adding an antiplatelet to oral anticoagulation does no good in atrial fib patients who've undergone stenting, how pill burden affects the ability to reach systolic BP control, and expert advice on how to get on top of home BP monitoring.
From the publisher's feed